Physician profile
Daniel Paul Erhardt
NPI 1467870212
$7,010.59
in general payments reported to CMS, 2019-2025
30 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $1,086 · 2021: $739 · 2022: $910 · 2023: $2,392 · 2024: $877 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331 · Education: $50.65 · Consulting Fee: $24.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,331.10 |
| Education | $50.65 |
| Consulting Fee | $24.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,351.38 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $1,121.53 | 2019-2024 | |
| Abbvie INC. | $732.68 | 2019-2024 | |
| Horizon Therapeutics Plc | $672.12 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $671.45 | 2021-2024 | Saphnelo |
| Ucb, INC. | $437.58 | 2019-2024 | Cimzia |
| Genentech USA, INC. | $348.49 | 2019-2024 | Actemra, Rituxan |
| Glaxosmithkline, LLC. | $335.74 | 2019-2024 | Benlysta |
| Sobi, INC | $210.49 | 2020-2024 | |
| Janssen Biotech, INC. | $152.65 | 2019-2023 | Simponi Aria, Remicade, Stelara |
| Novartis Pharmaceuticals Corporation | $135.76 | 2019-2022 | |
| Lilly USA, LLC | $121.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.34 | 2019-2024 | Cyltezo |
| Kyowa Kirin, INC. | $97.93 | 2025 | |
| Aurinia Pharma U.S., INC. | $58.39 | 2022-2024 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $54.92 | 2023 | Acthar |
| Mylan Institutional INC. | $53.04 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $52.26 | 2024-2025 | Orencia |
| Celltrion USA INC. | $50.65 | 2023 | Yuflyma |
| Regeneron Healthcare Solutions, INC. | $35.70 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $34.48 | 2022 | |
| Adma Biomanufacturing LLC | $24.07 | 2023 | |
| Fresenius Kabi USA, LLC | $22.49 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $21.66 | 2019 | |
| Biocon Biologics INC | $20.60 | 2023 | Hulio |
| Ultragenyx Pharmaceutical INC. | $20.40 | 2022 | |
| Radius Health, INC. | $17.16 | 2023 | Tymlos |
| Idorsia Pharmaceuticals US INC | $13.93 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $12.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Erhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.